<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>5(8)</volume><submitter>Ason B</submitter><pubmed_abstract>Heart failure (HF) remains a grievous illness with poor prognosis even with optimal care. The apelin receptor (APJ) counteracts the pressor effect of angiotensin II, attenuates ischemic injury, and has the potential to be a novel target to treat HF. Intravenous administration of apelin improves cardiac function acutely in patients with HF. However, its short half-life restricts its use to infusion therapy. To identify a longer acting APJ agonist, we conducted a medicinal chemistry campaign, leading to the discovery of potent small-molecule APJ agonists with comparable activity to apelin by mimicking the C-terminal portion of apelin-13. Acute infusion increased systolic function and reduced systemic vascular resistance in 2 rat models of impaired cardiac function. Similar results were obtai</pubmed_abstract><journal>JCI insight</journal><pagination>132898</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7205427</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cardiovascular response to small-molecule APJ activation.</pubmed_title><pmcid>PMC7205427</pmcid><pubmed_authors>Gao B</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Mihardja S</pubmed_authors><pubmed_authors>Guo Q</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Swaminath G</pubmed_authors><pubmed_authors>Fielden M</pubmed_authors><pubmed_authors>Boden A</pubmed_authors><pubmed_authors>Houze J</pubmed_authors><pubmed_authors>Vargas HM</pubmed_authors><pubmed_authors>Khakoo AY</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Qu Y</pubmed_authors><pubmed_authors>Chen R</pubmed_authors><pubmed_authors>Hoagland KM</pubmed_authors><pubmed_authors>Wong J</pubmed_authors><pubmed_authors>Ason B</pubmed_authors><pubmed_authors>Sutherland W</pubmed_authors><pubmed_authors>Chintalgattu V</pubmed_authors><pubmed_authors>Turk JR</pubmed_authors><pubmed_authors>Hu LA</pubmed_authors><pubmed_authors>Dransfield P</pubmed_authors><pubmed_authors>Chan J</pubmed_authors><pubmed_authors>Veniant MM</pubmed_authors><pubmed_authors>Nguyen K</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Li N</pubmed_authors><pubmed_authors>Rajamani S</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Chui RW</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Pattaropong V</pubmed_authors><pubmed_authors>Liu D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cardiovascular response to small-molecule APJ activation.</name><description>Heart failure (HF) remains a grievous illness with poor prognosis even with optimal care. The apelin receptor (APJ) counteracts the pressor effect of angiotensin II, attenuates ischemic injury, and has the potential to be a novel target to treat HF. Intravenous administration of apelin improves cardiac function acutely in patients with HF. However, its short half-life restricts its use to infusion therapy. To identify a longer acting APJ agonist, we conducted a medicinal chemistry campaign, leading to the discovery of potent small-molecule APJ agonists with comparable activity to apelin by mimicking the C-terminal portion of apelin-13. Acute infusion increased systolic function and reduced systemic vascular resistance in 2 rat models of impaired cardiac function. Similar results were obtai</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Apr</publication><modification>2026-05-03T05:26:29.696Z</modification><creation>2025-04-05T15:28:29.009Z</creation></dates><accession>S-EPMC7205427</accession><cross_references><pubmed>32208384</pubmed><doi>10.1172/jci.insight.132898</doi></cross_references></HashMap>